Results 11 to 20 of about 3,144,476 (264)

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2 [PDF]

Molecular Therapy: Oncolytics, 2021
Although oxaliplatin is an effective chemotherapeutic drug commonly used for colorectal cancer (CRC) treatment, drug resistance usually occurs during the long-term use of it.
Wei Sun, Yang Ge, Junpeng Cui, Yifan Yu, Baolin Liu   +4 more
doaj   +3 more sources

Targeting FBXL5 to induce ferroptosis and reverse oxaliplatin resistance in iron-rich colorectal cancer [PDF]

Scientific Reports
Oxaliplatin resistance remains a major challenge in colorectal cancer (CRC) treatment. We investigated the FBXL5/IREB2/TFRC axis in ferroptosis-mediated resistance reversal.
Miaomiao Wang, Ruizhe Zhang, Shuang He, Feifei Wen, Xiaojie Yu, Xiaoyang Xu, Yangyang Li, Shuhua Wu   +7 more
doaj   +2 more sources

Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer

Advanced Science, 2023
Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer (CRC); however, frequent drug resistance limits its therapeutic efficacy in patients.
Kaixuan Zeng, Weihao Li, Yue Wang, Zifei Zhang, Linjie Zhang, Weili Zhang, Yue Xing, Chi Zhou   +7 more
doaj   +2 more sources

NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer. [PDF]

World J Gastroenterol
BACKGROUND Glycolysis provides growth advantages and leads to drug resistance in colorectal cancer (CRC) cells. SIRT1, an NAD+-dependent deacetylase, regulates various cellular processes, and its upregulation results in antitumor effects.
Niu YR, Xiang MD, Yang WW, Fang YT, Qian HL, Sun YK.   +5 more
europepmc   +2 more sources

Influence of Citrobacter freundii on NINJ2 Expression and Oxaliplatin Resistance in Colorectal Cancer [PDF]

Cancer Medicine
Background Oxaliplatin, a third‐generation platinum‐based chemotherapeutic agent, is widely used in the treatment of colorectal cancer (CRC). However, some patients do not respond effectively to oxaliplatin, and intrinsic resistance to the drug poses a ...
Reio Ueta, Hiroo Imai, Ken Saijo, Yoshifumi Kawamura, Shuto Kodera, Chikashi Ishioka   +5 more
doaj   +2 more sources

NLRP3/IL‐1β induced myeloid‐derived suppressor cells recruitment and PD‐L1 upregulation promotes oxaliplatin resistance of hepatocellular carcinoma

MedComm, 2023
Oxaliplatin is commonly used as the first‐line chemotherapeutic agent for advanced hepatocellular carcinoma (HCC). Unfortunately, the acquired resistance, limits the effectiveness of oxaliplatin and the underlying mechanisms remain unknown. Therefore, we
Wenfeng Liu, Feng Zhang, Bing Quan, Fan Yao, Rongxin Chen, Zhenggang Ren, Xin Yin   +6 more
doaj   +2 more sources

PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer

Nature Communications, 2023
Despite being an effective treatment for hepatocellular carcinoma (HCC), resistance to oxaliplatin presents a major obstacle. Here, the authors identify PRMT3-induced methylation of IGF2BP1 resulting in HEG1 stabilisation as a mechanism of oxaliplatin ...
Yunxing Shi, Yi Niu, Yichuan Yuan, Kai Li, Chengrui Zhong, Zhiyu Qiu, Keren Li, Zhu Lin, Zhiwen Yang, Dinglan Zuo, Jiliang Qiu, Wei He, Chenwei Wang, Yadi Liao, Guocan Wang, Yunfei Yuan, Binkui Li   +16 more
doaj   +2 more sources

Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer

Journal of Translational Medicine
Background Oxaliplatin resistance usually leads to therapeutic failure and poor prognosis in colorectal cancer (CRC), while the underlying mechanisms are not yet fully understood.
Yuting Huang, Szehoi Chan, Shuna Chen, Xueqi Liu, Miao Li, Liyuan Zheng, Zhaoxia Dong, Ziyi Yang, Zixuan Liu, Disheng Zhou, Xingding Zhang, Bo Zhang   +11 more
doaj   +2 more sources

A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer

Cell Death and Disease, 2021
Long noncoding RNAs (lncRNAs) have emerged as a new class of regulatory molecules implicated in therapeutic resistance, yet the mechanisms underlying lncRNA-mediated oxaliplatin resistance in colorectal cancer (CRC) are poorly understood.
Xuan Deng, Fanyang Kong, Si Li, Haoqin Jiang, Liu Dong, Xiao Xu, Xinju Zhang, Hong Yuan, Ying Xu, Yimin Chu, Haixia Peng, Ming Guan   +11 more
doaj   +2 more sources

HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1

International Journal of Oncology, 2023
DNA double-strand break repair is critically involved in oxaliplatin resistance in pancreatic ductal adenocarcinoma (PDAC). Hepatocyte nuclear factor 1 homeobox A (HNF1A) has received increased attention regarding its role in cancer progression.
Renpeng Xia, Chonghui Hu, Yuancheng Ye, Xiang Zhang, Tingting Li, Rihua He, Shangyou Zheng, Xiaofeng Wen, Rufu Chen   +8 more
semanticscholar   +3 more sources